PMID- 36952521
OWN - NLM
STAT- MEDLINE
DCOM- 20230327
LR  - 20230419
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 18
IP  - 3
DP  - 2023
TI  - Efficacy of continuous positive airway pressure on TNF-alpha in obstructive sleep 
      apnea patients: A meta-analysis.
PG  - e0282172
LID - 10.1371/journal.pone.0282172 [doi]
LID - e0282172
AB  - BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) is an important mediator of the 
      immune response. At present, the improvement of TNF-alpha after continuous positive 
      airway pressure (CPAP) treatment of obstructive sleep apnea-hypopnea syndrome 
      (OSAHS) is still controversial. METHODS: We conducted a systematic review of the 
      present evidence based on a meta-analysis to elucidate the effects of TNF-alpha on 
      OSAHS after CPAP treatment. RESULTS: To measure TNF-alpha, ten studies used 
      enzyme-linked immunosorbent assay (ELISA), and one used radioimmunoassay. The 
      forest plot outcome indicated that CPAP therapy would lower the TNF-alpha levels in 
      OSAHS patients, with a weighted mean difference (WMD) of 1.08 (95% CI: 0.62-1.55; 
      P < 0.001) based on the REM since there is highly significant heterogeneity (I2 = 
      90%) among the studies. Therefore, we used the subgroup and sensitivity analyses 
      to investigate the source of heterogeneity. The findings of the sensitivity 
      analysis revealed that the pooled WMD ranged from 0.91 (95% CI: 0.52-1.31; P < 
      0.001) to 1.18 (95% CI: 0.74-1.63; P < 0.001). The findings were not influenced 
      by any single study. Notably, there was homogeneity in the Asia subgroup and 
      publication year: 2019, implying that these subgroups could be the source of 
      heterogeneity. CONCLUSION: Our meta-analysis recommends that CPAP therapy will 
      decrease the TNF-alpha level in OSAHS patients, but more related research should be 
      conducted.
CI  - Copyright: (c) 2023 Luo et al. This is an open access article distributed under the 
      terms of the Creative Commons Attribution License, which permits unrestricted 
      use, distribution, and reproduction in any medium, provided the original author 
      and source are credited.
FAU - Luo, Yong
AU  - Luo Y
AD  - Department of Otorhinolaryngology, The First People's Hospital of Jiangxia 
      District, Union Jiangnan Hospital Huazhong University of Science and Technology, 
      Wuhan, Hubei, China.
FAU - Zhang, Fa-Rong
AU  - Zhang FR
AD  - Department of Otorhinolaryngology, The First People's Hospital of Jiangxia 
      District, Union Jiangnan Hospital Huazhong University of Science and Technology, 
      Wuhan, Hubei, China.
FAU - Wu, Jun-Lin
AU  - Wu JL
AD  - Department of Endocrinology, Fifth Hospital in Wuhan, Wuhan, Hubei, China.
FAU - Jiang, Xi-Jiao
AU  - Jiang XJ
AUID- ORCID: 0000-0002-3194-5643
AD  - Department of Otorhinolaryngology, The First People's Hospital of Jiangxia 
      District, Union Jiangnan Hospital Huazhong University of Science and Technology, 
      Wuhan, Hubei, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20230323
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Humans
MH  - *Tumor Necrosis Factor-alpha
MH  - Continuous Positive Airway Pressure
MH  - *Sleep Apnea, Obstructive/therapy
MH  - Syndrome
MH  - Enzyme-Linked Immunosorbent Assay
PMC - PMC10035913
COIS- The authors have declared that no competing interests exist.
EDAT- 2023/03/24 06:00
MHDA- 2023/03/28 06:00
PMCR- 2023/03/23
CRDT- 2023/03/23 14:23
PHST- 2022/05/07 00:00 [received]
PHST- 2023/02/08 00:00 [accepted]
PHST- 2023/03/23 14:23 [entrez]
PHST- 2023/03/24 06:00 [pubmed]
PHST- 2023/03/28 06:00 [medline]
PHST- 2023/03/23 00:00 [pmc-release]
AID - PONE-D-22-12567 [pii]
AID - 10.1371/journal.pone.0282172 [doi]
PST - epublish
SO  - PLoS One. 2023 Mar 23;18(3):e0282172. doi: 10.1371/journal.pone.0282172. 
      eCollection 2023.